µðÁöÅÐ ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : ÀÓ»ó Áø·áº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹® ¿¹Ãø(2025-2030³â)
Digital Neuro Biomarkers Market Size, Share & Trend Analysis Report By Type (Wearable, Mobile based Applications), By Clinical Practice, By End Use, By Region, and Segment Forecasts, 2025 - 2030
»óǰÄÚµå : 1631563
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2024³â 12¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 100 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,609,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,950 £Ü 10,055,000
Printable PDF (5-User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,949,000
Printable PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

µðÁöÅÐ ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :

¼¼°èÀÇ µðÁöÅÐ ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå ±Ô¸ð´Â 2030³â¿¡´Â 28¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í, 2025³âºÎÅÍ 2030³â¿¡ °ÉÃÄ CAGRÀº 25.7%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½Å°æÁúȯ À¯º´·ü Áõ°¡, ¼¼°è ³ëÀÎ Àα¸ Áõ°¡, ±â¼ú Áøº¸, ¸ÂÃãÇü ÀÇ·á ¼ö¿ä, ¹Î°£ ¹× °ø°ø ±â¾÷¿¡ ÀÇÇÑ ½ÃÀå ÅõÀÚ Áõ°¡ µî ´Ù¾çÇÑ ¿äÀÎÀ¸·Î ½ÃÀåÀÌ Å« ¼ºÀåÀ» ÀÌ·ç°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ µðÁöÅÐ Çコ ±â¼ú¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀΰú »óȯ ¹üÀ§ÀÇ È®´ë°¡ µðÁöÅÐ ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿ÀÇ Ã¤¿ëÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦±â°üÀº ȯÀÚ °á°ú¸¦ °³¼±ÇÏ´Â ÀÌ·¯ÇÑ ±â¼úÀÇ ÀáÀç·ÂÀ» ÀνÄÇϰí ÀÖÀ¸¸ç, ÁöÁö Á¤Ã¥°ú »óȯ ¸ðµ¨·Î À̾îÁö°í ÀÖ½À´Ï´Ù.

¾ËÃ÷ÇÏÀ̸Ӻ´, ÆÄŲ½¼º´, ´Ù¹ß¼º °æÈ­Áõ µî ½Å°æÁúȯÀÇ À¯º´·ü Áõ°¡´Â µðÁöÅÐ ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿ ¼ö¿ä¸¦ Å©°Ô ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÑ Áúº´Àº Áõ»óÀ» È¿°úÀûÀ¸·Î °ü¸®Çϰí ȯÀÚÀÇ °á°ú¸¦ °³¼±Çϱâ À§ÇØ Á¤È®Çϰí Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µ°ú Á¶±â ¹ß°ßÀÌ ÇÊ¿äÇÕ´Ï´Ù. µðÁöÅÐ ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿´Â ¿þ¾î·¯ºí ¼¾¼­ ¹× ¸ð¹ÙÀÏ Çコ ¿ëµµ°ú °°Àº °í±Þ ±â¼úÀ» ÅëÇØ ½Å°æ ±â´É°ú Áúº´ÀÇ ÁøÇàÀ» Á¤È®ÇÏ°Ô ÃßÀûÇÕ´Ï´Ù. ½Ç½Ã°£ µ¥ÀÌÅÍ¿Í ÅëÂû·ÂÀ» Á¦°øÇÔÀ¸·Î½á ÀÌ·¯ÇÑ ¹ÙÀÌ¿À¸¶Ä¿´Â Á¶±â °³ÀÔ°ú ¸ÂÃã Ä¡·á Àü·«À» °¡´ÉÇÏ°Ô ÇÏ°í ½Å°æÁúȯÀÇ Àû½Ã¿¡ Àû±ØÀûÀÎ °ü¸®¶ó´Â Áß¿äÇÑ ¿ä±¸¿¡ ´ëÀÀÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹¿¡¼­´Â 100¸¸ ¸í °¡±îÀÌ ´Ù¹ß¼º °æÈ­Áõ(MS)ÀÇ ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. Àü¹Ì ´Ù¹ß¼º °æÈ­Áõ Çùȸ¿¡ µû¸£¸é Àü ¼¼°èÀûÀ¸·Î 280¸¸ ¸í ÀÌ»óÀÌ MS¿Í ÇÔ²² »ì°í ÀÖ´Â °ÍÀ¸·Î ÃßÁ¤µÇ°í ÀÖ½À´Ï´Ù. MS·Î Áø´ÜµÇ´Â °ÍÀº 20-50¼¼°¡ ¸¹Áö¸¸, ¿¬·É¿¡ °ü°è¾øÀÌ ¹ßº´ÇÒ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. ¶ÇÇÑ MS´Â ³²¼º¿¡ ºñÇØ ¿©¼º¿¡°Ô ¸¹ÀÌ Áø´ÜµË´Ï´Ù.

½Å°æ ÁúȯÀÇ Á¶±â ¹ß°ß°ú ¿¹¹æÀÌ Á߽õǰí ÀÖ½À´Ï´Ù. µðÁöÅÐ ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿´Â ÀüÅëÀûÀÎ ¹æ¹ýº¸´Ù Ãʱ⠴ܰ迡¼­ Áúº´ ¸¶Ä¿¸¦ °ËÃâÇÒ ¼ö ÀÖÀ¸¹Ç·Î Àû½Ã¿¡ °³ÀÔ ¹× °ü¸®°¡ °¡´ÉÇÏ´Ù´Â ÀåÁ¡ÀÌ ÀÖ½À´Ï´Ù. AI¿Í ¸Ó½Å·¯´×ÀÇ ÅëÇÕµµ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖÀ¸¸ç, ¿¹¸¦ µé¾î 2022³â 9¿ù Nutromics»ç´Â 'lab-in-a-patch' Ç÷§ÆûÀ» ÃßÁøÇϱâ À§ÇØ Dexcom Ventures»ç·ÎºÎÅÍ 1,400¸¸ ´Þ·¯ÀÇ ÀÚ±ÝÀ» È®º¸Çß½À´Ï´Ù. ÀÌ Çõ½ÅÀûÀÎ ±â¼úÀº DNA ¼¾¼­¸¦ Ȱ¿ëÇÏ¿© Áúº´ ¹ÙÀÌ¿À¸¶Ä¿ ¹× °úÁ¦ Ä¡·áÁ¦¸¦ Æ÷ÇÔÇÑ ´Ù¾çÇÑ ´ë»óÀ» ¸ð´ÏÅ͸µÇÕ´Ï´Ù. ¶ÇÇÑ µðÁöÅÐ ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿¸¦ ÀüÀÚ ÀÇ·á ±â·Ï(EHR) ¹× ¿ø°Ý ÀÇ·á¿Í °°Àºº¸´Ù ±¤¹üÀ§ÇÑ µðÁöÅÐ °Ç°­ Ç÷§Æû°ú ÅëÇÕÇϸé À¯¿ë¼º°ú Á¢±Ù¼ºÀÌ Çâ»óµË´Ï´Ù. ÀÌ ÅëÇÕÀº Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µ°ú ½Ç½Ã°£ µ¥ÀÌÅÍ ºÐ¼®À» ¿ëÀÌÇÏ°Ô Çϰí ȯÀÚ °ü¸® ¹× °á°ú¸¦ °³¼±ÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 10¿ù, ÷´Ü ½Å°æÁúȯ Áø´ÜÀÇ °³¹ß¿¡ ÀÓÇÏ´Â AI ±â¾÷ÀÎ ¾ËÅäÀÌ´Ù´Â 5³â°£ ´Ù½Ã¼³ °üÂû ¿¬±¸¸¦ ½ÃÀÛÇß½À´Ï´Ù. ÀÌ ±¤¹üÀ§ÇÑ Á¶»ç´Â ¾ËÃ÷ÇÏÀÌ¸Ó º´ÀÇ Àü ´Ü°è¿¡ °ÉÃÄ ¼öõ ¸íÀÇ È¯ÀÚ¸¦ ´ë»óÀ¸·Î Áúº´ ¿¬¼Óü¸¦ ÀÌÇØÇϰí Áø´Ü ´É·ÂÀ» Çâ»ó½ÃŰ´Â °ÍÀ» ¸ñÇ¥·ÎÇÕ´Ï´Ù.

ÁÖ¿ä ±â¾÷Àº ÇÕº´, Àμö, Á¦Ç° Ãâ½Ã µî °æÀï·ÂÀ» À¯ÁöÇϱâ À§ÇØ ´Ù¾çÇÑ Àü·«À» äÅÃÇϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä ½ÃÀå ÁøÃâ ±â¾÷ÀÇ ÁÖ¿ä Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê´Â ´ÙÀ½°ú °°½À´Ï´Ù.

µðÁöÅÐ ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : ºÐ¼® °³¿ä

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå µðÁöÅÐ ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå µðÁöÅÐ ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : À¯Çüº° ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦5Àå µðÁöÅÐ ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : ÀÓ»ó Áø·áº° ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦6Àå µðÁöÅÐ ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦7Àå µðÁöÅÐ ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : Áö¿ªº° ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦8Àå °æÀï ±¸µµ

KTH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Digital Neuro Biomarkers Market Growth & Trends:

The global digital neuro biomarkers market size is anticipated to reach USD 2.82 billion in 2030 and is projected to grow at a CAGR of 25.7% from 2025 to 2030. The market is witnessing significant growth owing to various factors such as increased prevalence of neurological disorders, rising geriatric population globally, advances in technology, demand for personalized medicine, and increased investment in the market by private and public players. Furthermore, positive regulatory approvals and increasing reimbursement coverage for digital health technologies encourage the adoption of digital neuro biomarkers. Regulatory bodies are recognizing the potential of these technologies to improve patient outcomes, leading to supportive policies and reimbursement models.

The increasing prevalence of neurological disorders such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis is significantly fueling the demand for digital neuro biomarkers. These complex conditions necessitate accurate, continuous monitoring and early detection to manage symptoms effectively and improve patient outcomes. Digital neuro biomarkers, through advanced technologies such as wearable sensors and mobile health applications, offer precise tracking of neurological functions and disease progression. By providing real-time data and insights, these biomarkers enable early intervention and personalized treatment strategies, addressing the critical need for timely and targeted management of neurological conditions. For instance, in the U.S., close to 1 million individuals are impacted by multiple sclerosis (MS). Globally, it is estimated that over 2.8 million people are living with MS, according to the National Multiple Sclerosis Society. While most MS diagnoses occur between the ages of 20 and 50, the condition can affect individuals at any age. In addition, MS is more commonly diagnosed in women compared to men.

There is a growing emphasis on early detection and prevention of neurological diseases. Digital neuro biomarkers offer the advantage of detecting disease markers at an earlier stage than traditional methods, allowing for timely intervention and management. Integration of AI and machine learning is also driving the market growth, for instance, in September 2022, Nutromics secured USD 14 million in funding from Dexcom Ventures to advance its 'lab-in-a-patch' platform. This innovative technology utilizes DNA sensors to monitor a range of targets, including disease biomarkers and challenging-to-dose medications. Moreover, the integration of digital neuro biomarkers with broader digital health platforms, including electronic health records (EHRs) and telemedicine, enhances their utility and accessibility. This integration facilitates continuous monitoring and real-time data analysis, improving patient care and outcomes. For instance, In October 2021, Altoida, Inc., an AI company at developing advanced neurological disease diagnostics, launched a five-year multicenter observational study. This extensive study will involve thousands of patients across all stages of Alzheimer's disease, aiming to enhance the understanding and diagnostic capabilities of the disease continuum.

Key players are adopting various strategies to maintain a competitive edge such as mergers, acquisition, product launches, etc. Some of the key strategic initiatives by the major market players include:

Digital Neuro Biomarkers Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Digital Neuro Biomarkers Market Variables, Trends & Scope

Chapter 4. Digital Neuro Biomarkers Market: Type Estimates & Trend Analysis

Chapter 5. Digital Neuro Biomarkers Market: Clinical Practice Estimates & Trend Analysis

Chapter 6. Digital Neuro Biomarkers Market: End Use Estimates & Trend Analysis

Chapter 7. Digital Neuro Biomarkers Market: Regional Estimates & Trend Analysis

Chapter 8. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â